Real-world effectiveness of CDK 4/6 inhibitors in estrogen-positive metastatic breast cancer
{{output}}
Background: Initial treatment for advanced ER-positive/HER2-negative breast cancer involves a CDK 4/6 inhibitor (CDK 4/6i). Recent overall survival (OS) analyses led the Danish Medical Council to exclude palbociclib as preferred ... ...
